Core Viewpoint - The acquisition of a 40% stake in Huaxi Kangshengda by Wuhan Kangshengda is a strategic move to enhance the company's control over its operations and align with its overall business strategy in the southwestern region of China [1][2]. Group 1: Transaction Details - Wuhan Kangshengda successfully acquired a 40% stake in Huaxi Kangshengda from Huaxi Health Technology for a consideration of RMB 12.396 million [1]. - Following the completion of this transaction, Huaxi Kangshengda will become an indirect wholly-owned subsidiary of the company [2]. Group 2: Strategic Importance - Huaxi Kangshengda serves as a core platform for the company's "national special inspection network + regional center laboratory" strategy in the southwestern region, providing high-end special inspection services across Sichuan, Chongqing, Yunnan, and Guizhou [2]. - The full ownership will enhance the company's management and strategic direction over Huaxi Kangshengda, ensuring efficient execution of the overall strategy in the southwestern region [2]. - As a leading third-party medical testing (ICL) platform, Huaxi Kangshengda will support the company's dual-track development strategy of "ICL + IVD," promoting synergy between ICL-driven IVD product development and IVD service upgrades [2].
康圣环球(09960.HK)拟1239.6万元收购华西康圣达40%股权